Evaluation of Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors.

Background: Lu peptide receptor radionuclide therapy (PRRT) is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine tumors.

Aim: To determine the impact of PRRT on quality of life, radiologic and metabolic response, overall survival, prognostic factors and toxicity.

Methods: Thirty-six patients treated with Lu-PRRT from 2016 to 2019 were included.

Advantages and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in the diagnosis of infective endocarditis.

Introduction: The early diagnosis of infective endocarditis (IE) is a medical challenge and a multidisciplinary approach is essential to improve its frequently fatal prognosis. Our goal was to evaluate the usefulness of [F]2-fluoro-2-deoxy-d-glucose positron emission tomography (F-FDG PET) in the diagnosis of this disease.

Materials And Methods: We prospectively assessed 43 patients (five female and 38 male) with clinical suspicion of IE between 2014 and 2017.